Impact of GLP-1 Receptor Agonist Therapy on Alcohol Pharmacokinetics
University of Wisconsin, Madison
Summary
This study is to learn how the weight loss drug tirzepatide (Zepbound) changes the way a body handles alcohol. 5 participants aged 21-55 who take Zepbound will be enrolled and can expect to be on study for up to 4 weeks.
Description
Participants will: * Arrive to study visit in a fasted state * Provide blood, breath, and urine samples prior to intervention * Complete baseline cognitive assessments * Self-administer the intervention (time 0), followed by breakfast (time 30 minutes) * Complete subjective and cognitive assessments throughout treatment visit * Provide blood, breath, and urine samples throughout treatment visit * Consume lunch 260 minutes after dosing * Complete study visit at 360 minutes * Complete a final study survey Primary Objective: Characterize the pharmacokinetics of ethanol in participants receiving…
Eligibility
- Age range
- 21–55 years
- Sex
- All
- Healthy volunteers
- Yes
Inclusion Criteria: * At least 21 years of age, no older than 55 years of age * BMI 30-45 kg/m2 * Taking stable dose of prescribed, branded tirzepatide for at least 28 days * Self-reported regular alcohol consumption * Good mental health as determined by self-reported responses to the Psychopathology Screener and review by Study Physician as necessary * Absence of any major medical, cardiovascular, endocrine, and neurological condition as determined by self-reported responses to the Medical History Screener * In possession of a valid drivers' license with at least two years of driving experie…
Interventions
- DrugAcute Ethanol Dose
Time 0, participants will self-administer an oral ethanol beverage (vodka and sugar-free cherry Kool aid) calculated to reach a peak Breath Alcohol Concentration (BrAC) of 0.08 g/dL using the Widmark formula. A total time of 30 minutes will be given for completion of beverage consumption. This will be followed by a breakfast.
Location
- University of WisconsinMadison, Wisconsin